Roche's Tarceva wins NICE nod for first-line use - FiercePharma

The U.K.'s cost-effectiveness watchdog has changed its mind about Tarceva. After an initial draft guidance rejecting the lung cancer treatment, the National Institute for Health and Clinical Excellence now says Tarceva should be available as a ...

Tarceva could be given to patients across all types of lung cancer - Medical News Today

The NICE decision, on having NHS cover Tarceva as a first-line treatment for patients with lung cancer, may be a double-edge sword. Despite high response rates in mutation positive patients, approximately 30-40% of patients with the appropriate biomarker ...

Research and Markets: Tarceva (Pancreatic Cancer) - Analysis and Forecasts to 2020 - Boston Globe

Dublin - Research and Markets (http://www.researchandmarkets.com/research/qw6kmn/tarceva_pancreati) has announced the addition of GlobalData 's new report "Tarceva (Pancreatic Cancer) - Analysis and Forecasts to 2020" to their offering.

Astellas announces favorable judgment in patent infringement case - comcast.net

5,747,498 (reissued as RE 41,065) and 6,900,221, which cover Tarceva (erlotinib) tablets and their use. The lawsuit was based on an Abbreviated New Drug Application (ANDA) filed by Mylan seeking permission from the FDA to manufacture and market a generic ...

Class Of Cancer Drugs Linked To Eye Infections, MHRA Warns - Newsinferno.com

Erbitux (cetuximab), Tarceva (erlotinib), Iressa (gefitinib) and Vectibix, are used to treat EGFR-expressing tumors. The cornea is covered with a layer of epithelium, which may become damaged when patients are receiving EGFR treatment.

22 Biopharma Stocks With Breakout Potential in 2012 - Inside Fidelity

The "MARQUEE" trial compares tivantinib plus Takeda's Tarceva against Tarceva alone in previously treated non-small cell lung cancer patients. The study's primary endpoint is overall survival. Peyronie's is a buildup of scar tissue that causes extreme (and ...

OSI Pharmaceuticals, Inc. - Strategic SWOT Analysis Review - new company profile report - Transworld News

The company's flagship product is Tarceva, a small molecule inhibitor of the epidermal growth factor receptor (EGFR) in the Oncology segment. The company's product pipeline include Erlotinib tablets, OSI-906, OSI-027, OSI-930 for oncology, PSN821 ...

Cancer pill effective, but copay higher - USA Today

"But if a patient needs a new targeted therapy like the lung-cancer drug Tarceva, he may end up paying a substantially higher percentage of the cost than he would have had there been a comparable intravenous drug." There is no oral oncology ...

Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality Reduction - msnbc.com

Doxorubicin liposomal (Doxil), Eribulin (Halaven), Erlotinib (Tarceva), Everolimus (Afinitor), Exemestane (Aromasin), Fadrozole (Afema), Fluoxymesterone, Fulvestrant (Faslodex), Ganitumab, Gemcitabine (Gemzar), Goserelin (Zoladex), Herceptin SC ...

Idera Pharmaceuticals Announces Efficacy Data for IMO-8400 in Preclinical Models of Lupus and Psoriasis - TMCnet

Erbitux® is a registered trademark of ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company. Tarceva® is a registered trademark of OSI Pharmaceuticals, LLC, an affiliate of Astellas Pharma US, Inc. Avastin® is a registered trademark ...